Hamilton Health Sciences Corporation

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intravascular Ultrasound for Peripheral Artery Disease Revascularization

Not Applicable

Not yet recruiting

Conditions: Peripheral Arterial Disease(PAD)
Chronic Limb Threatening Ischemia
Intravascular Ultrasound
Major Adverse Limb Events
Restenosis

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 772

Registration Number: NCT06979284

Health Literacy in Geriatric Patients

Recruiting

Conditions: Health Literacy

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 100

Registration Number: NCT06971393

Locations: 🇨🇦
St. Peter's Geriatric Clinic, Hamilton, Ontario, Canada

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Phase 4

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Semaglutide Pen Injector

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-03

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 20

Registration Number: NCT06908694

Locations: 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

SCORE! ACTIVE Trial

Not Applicable

Recruiting

Conditions: Chronic Disease
Childhood Obesity

First Posted Date: 2025-02-25

Last Posted Date: 2025-02-25

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 1400

Registration Number: NCT06844786

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada

A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation

Phase 2

Not yet recruiting

Conditions: Constipation - Functional
Constipation
Constipation Aggravated

Interventions: Dietary Supplement: Actazin chewable tablet
Drug: PEG 3350
Other: Chewable Tablet
Other: Maltodextrin (Placebo)

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-19

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 60

Registration Number: NCT06836024

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

CCTA to Optimize Diagnostic Yield of Invasive Angiography With AI

Not Applicable

Recruiting

Conditions: Coronary Artery Disease

First Posted Date: 2024-10-18

Last Posted Date: 2025-01-30

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 252

Registration Number: NCT06648239

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada
🇨🇦
St. Catharines Hospital, St. Catharines, Ontario, Canada

Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial

Phase 3

Not yet recruiting

Conditions: Bleeding
Surgical Blood Loss
Seizures

Interventions: Drug: After CPB Tranexamic Acid
Drug: Before CPB Tranexamic Acid
Drug: Before CPB Placebo
Drug: After CPB Placebo

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 40

Registration Number: NCT06622564

Locations: 🇨🇦
Hamilton Health Sciences - General Hospital, Hamilton, Ontario, Canada

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

Phase 4

Not yet recruiting

Conditions: Infection, Surgical Site

Interventions: Drug: Cefazolin
Drug: Vancomycin

First Posted Date: 2024-08-23

Last Posted Date: 2025-03-12

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 38000

Registration Number: NCT06567808

Vitaliti Continuous Vital Signs Monitor User-Testing Protocol: VERDICT-2

Not Applicable

Not yet recruiting

Conditions: Surgery

Interventions: Other: User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 45

Registration Number: NCT06464094

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada

Effect of Caffeine Consumption on Protein Biomarkers and Cardiovascular Disease

Early Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: Caffeine Pill
Drug: Placebo
Device: TASSO+ Device
Device: Finger prick and collection on Whatman Protein 903 Saver Cards
Device: Intravenous Sampling

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 36

Registration Number: NCT06359197

Locations: 🇨🇦
McMaster University, Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada
🇨🇦
David Braley Research Institute, Hamilton, Ontario, Canada
🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada

Home Terms & Conditions Privacy Policy